Eight consecutive quarters of beating expectations, CVS Health Corporation (CVS.US) plunged 12.5% overnight after its "one-for-two" split! Why hasn't the split led to a valuation re-rating?

On Wednesday, CVS Health Corporation (CVS.US) announced a one-for-two split while delivering its eighth consecutive quarter of earnings that beat expectations, with 2027 profit guidance also above Wall Street consensus. But the market responded in the exact opposite way: at the overnight close, the company's shares plunged 12.5%. For a company that had just "beaten expectations," this is a rare pricing response. What the market cares about is clearly not current-period profit. The real question is: after the split, why should these two businesses be worth more? According to the announcement, CVS will separate its retail pharmacy business from its Aetna insurance and pharmacy benefit management (PBM) businesses. The transaction amounts to breaking up a healthcare group that took years to build and is worth US$117 billion. The deal is expected to be completed in the first half of 2028, at which point CVS Health shareholders will hold shares in both companies. This also means that, since the acquisition of Caremark PBM in 2006, CVS's retail pharmacy business will return to independent operation for the first time. Over the following two decades, the company made a series of acquisitions, including the US$78 billion purchase of Aetna in 2018. The post-spin-off structure has already been set: CVS Health Corporation will continue to be led by current CEO David Joyner, covering Aetna, Caremark, specialty pharmacy, and healthcare services companies Oak Street Health and Signify Health; Prem Shah, currently head of pharmacy and related businesses and healthcare delivery, will become CEO of CVS Pharmacy, with businesses including MinuteClinics clinics, mail-order pharmacy, and a consumer platform called Health100which uses data across insurers, medical institutions, and pharmacies to help patients manage their care. Judging by the numbers, this was originally an earnings report strong enough to support the share price. In the third quarter, the company reported earnings per share of US$2.09, far exceeding the average analyst estimate of US$1.65 surveyed by LSEGits eighth consecutive quarter of beating Wall Street expectations. The company's 2027 adjusted earnings per share guidance was no less than US$8.65, also above the average analyst estimate of US$8.53. Management also emphasized improving fundamentals. Joyner said that over the past two years, the company's 9,000-store pharmacy chain, Caremark's pharmacy benefit management business, and Aetna's insurance business all improved markedly, which is what made this structural adjustment possible. "All the businesses are running very well," he said in an interview. "We now have room to make different decisions, which I could not do two years ago." He recalled that when he took over two years ago, the company expected the pharmacy business to decline 5%; since then, CVS has upgraded store technology to boost capacity and adjusted its prescription drug reimbursement model so that it can maintain profitability on both branded and generic drugs while offering lower prices. At Aetna, the company had previously failed to meet financial targets because of miscalculations on Medicare Advantage plans for people aged 65 and over, and that has now also been repaired somewhat. Why doesn't this split earn a valuation re-rating? First, and most directly: the split plan lacks financial details, so investors cannot model it. Barclays analyst Andrew Mok explicitly listed "the lack of financial details around the split" as investors' top concern. He reminded the market of a reference point: when CVS Health Corporation acquired Caremark twenty years ago, it claimed the deal would generate at least US$500 million in synergies. By the same logic, a reverse split would likewise produce synergy losses; and this time, the company gave no quantitative explanation. How debt will be allocated between the two companies, how capital allocation policy will be arranged, and how large one-time separation costs will beall these questions that determine the denominator of valuation models are left blank. Second, what is being split off may not be the part that drew criticism. For years, industry consolidation has put companies such as CVS Health Corporation under dual pressure from regulators and consumers. Critics argue that these acquisitions created conflicts of interest among business lines and pushed up U.S. healthcare spendingthe highest level in the world. But this split carves out the retail pharmacy stores, while the focus of controversythe combination of insurance and PBMremains within the same entity. Morningstar analyst Julie Utterback's assessment is telling: "In recent years, vertical integration among managed care organizations has been criticized by both regulators and customers, and CVS has the largest exposure to this model in the industry." She believes "management probably thought that rather than waiting for a legal or legislative decision to force its hand, it was better to take this step now from a relatively proactive position." In other words, this is a preemptive move, not a cure. Regulatory risk has not disappeared because of the split; it has merely been repositioned. Third, the split itself comes at a cost. Two independent listed companies mean two management teams, two sets of compliance and investor relations costs, and the loss of the original cross-traffic referral, centralized procurement bargaining power, and back-office sharing capabilities. CVS's pharmacy network, Aetna's insurance members, and Caremark's prescription flow originally supported one another. After the split, this "internal dividend" will turn into external negotiation transaction costsand the market currently has no data to assess whether this calculation is worthwhile. Fourth, although guidance beats consensus, it is not superior relative to peers. Kevin Gade, chief operating officer of Bahl & Gaynor, noted that the US$8.65 2027 guidance is not attractive compared with peers: some competitors are more focused on government-led healthcare plans, and after Democrats decisively won control of Congress in Tuesday's midterm elections, such businesses may receive more political support next year. The same-day political variable weakened the relative value of CVS's guidance. Fifth, operational headwinds cannot be split away. Payment pressure on the pharmacy side remains, competition from Amazon.com, Inc. and other online pharmacies remains, and the trend toward prescription drug delivery has reduced store traffic that could drive ancillary spendingthis is also the increasingly difficult economic reality for large U.S. pharmacy chains. The insurance side is likewise under strain: post-pandemic consumer use of medical services has risen, and medical costs are broadly elevated across Medicare, Medicaid for low-income people, ACA plans, and commercial insurance. The company's own wording is hardly optimistic either: while raising its 2026 adjusted profit forecast to no less than US$8.2 per share, CVS Health Corporation said that given factors such as persistently high medical costs, it remains cautious about the rest of the year. Sixth, the market has heard this story before. Reuters previously reported that CVS Health Corporation explored various options in 2024, including a potential split, as the healthcare giant was dealing with multiple challenges across its business segments. Expectations had already been traded in advance; and when the plan finally materialized, what was delivered was only "whether it would split," not "how much it would be worth after splitting." More broadly, this split is the latest in a series of major corporate separations this decade. When spin-offs turn from individual cases into a trend, the narrative that "a split unlocks value" can hardly command a premium automatically anymorethe market begins to demand evidence, and CVS Health Corporation did not provide it this time. The industry backdrop is also not encouraging. Competitor Walgreens, after a lengthy sale process, sold its Boots pharmacy business last year, while the company itself was acquired by private equity firm Sycamore Partners. What the market buys has never been realized profit, but the future cash flow structure. Until questions such as how debt will be divided, how capital will be allocated, and how large the synergy losses will be are answered, this split plan is only a blueprint, not yet a valuation table. And the 12.5% decline is the price investors have put on those blanks.